Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562 is registered in ClinicalTrials.gov with IRIS Research and Development, LLC as lead sponsor.

NCT NCT06581562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Lead sponsor
IRIS Research and Development, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
May 15, 2024
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

granulomatosis with polyangiitis, pemphigus vulgaris, rheumatoid arthritis, systemic lupus erythematosus